Simple Summary PI3K signaling pathway plays an essential role in many cellular processes
and is frequently altered in breast cancer, leading to increased tumor growth and reduced …

Mammalian target of rapamycin (mTOR) is an atypical protein kinase that controls growth
and metabolism in response to nutrients, growth factors and cellular energy levels, and it is …

The last decade has brought a breakthrough in the knowledge of the biology of breast
cancer. The technological development, and in particular the high throughput technologies …

Purpose Cross-talk between signal transduction pathways likely contributes to hormone
resistance in metastatic breast cancer (mBC). Everolimus, an oral inhibitor of the mammalian …

Background Everolimus (RAD001) is an orally administered inhibitor of the mammalian
target of rapamycin (mTOR), a therapeutic target for metastatic renal cell carcinoma. We did …

Purpose This phase I dose-escalation study investigated the maximum-tolerated dose
(MTD), safety, preliminary activity, pharmacokinetics (PK), and pharmacodynamics of …

Numerous studies have established a causal link between aberrant mammalian target of
rapamycin (mTOR) activation and tumorigenesis, indicating that mTOR inhibition may have …

Understanding the molecular mechanisms underlying synergistic, potentiative and
antagonistic effects of drug combinations could facilitate the discovery of novel efficacious …

Purpose: In cancer cells, the epigenome is often deregulated, and inhibition of the
bromodomain and extra-terminal (BET) family of bromodomain-containing proteins is a …

The broadly active glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) has been
studied for 60 years as a potential anticancer therapeutic. Clinical studies of DON in the …